Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $9,334 | $4,074 |
| General and administrative | 5,521 | 3,797 |
| Total operating expenses | 14,855 | 7,871 |
| Operating loss | (14,855) | (7,871) |
| Other (expense) income: | ||
| Interest expense – royalty agreement | (2,039) | (1,215) |
| Fair value adjustments on derivative liabilities – royalty agreement | (116) | (75) |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's G&A?
- Palvella Therapeutics (PVLA) reported G&A of $5.52M in Q1 2026.
- How has Palvella Therapeutics's G&A changed year-over-year?
- Palvella Therapeutics's G&A increased by 45.4% year-over-year, from $3.8M to $5.52M.
- What is the long-term trend for Palvella Therapeutics's G&A?
- Over 2 years (2021 to 2025), Palvella Therapeutics's G&A has grown at a -2.5% compound annual growth rate (CAGR), from $16.59M to $15.76M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Palvella Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude